ClinicalTrials HQ

Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer

Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer

Active, not recruiting · NCT02712723 · Registry updated 2026-03-11
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 22026-03-11NCT02712723

2 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Novartis Pharmaceuticals432
Qamar Khan1

13 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Cancer Research CollaborationSanta AnaUnited States1
City of Hope National Medical CenterDuarteUnited States68
Columbia University Medical centerNew YorkUnited States224
Massachusetts General HospitalBostonUnited States1015
University of Arkansas for Medical SciencesLittle RockUnited States218
University of Kansas Cancer Center - Lee's SummitLee's SummitUnited States158
University of Kansas Cancer Center - NorthKansas CityUnited States162
University of Kansas Cancer Center - Overland ParkOverland ParkUnited States4
University of Kansas Cancer Center - SouthKansas CityUnited States2
University of Kansas Cancer Center - WestKansas CityUnited States2
University of Kansas Cancer Center - WestwoodWestwoodUnited States6
University of Miami Sylvester Comprehensive Cancer CenterDeerfield BeachUnited States2
University of Wisconsin Carbone Cancer CenterMadisonUnited States14